Stock Research: Zydus

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Zydus

NSEI:CADILAHC INE010B01027
20
  • Value
    55
  • Growth
    7
  • Safety
    Safety
    63
  • Combined
    24
  • Sentiment
    32
  • 360° View
    360° View
    20
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Zydus Lifesciences Limited is an India-based global life sciences company focused on discovering, developing, manufacturing, and marketing healthcare therapies. Its main businesses include integrated pharmaceutical operations, active pharmaceutical ingredients (API), human formulations, animal health and veterinary products, and health and wellness products, with products like Lipaglyn and Ujvira. The company has a global presence, marketing products in the United States, India, Europe, and emerging markets. In the last fiscal year, the company had a market cap of $11341 million, profits of $1978 million, and revenue of $2720 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 20 (better than 20% compared with alternatives), overall professional sentiment and financial characteristics for the stock Zydus are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Zydus. The consolidated Value Rank has an attractive rank of 63, which means that the share price of Zydus is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 63% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 55. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 32. Professional investors are more confident in 68% other stocks. The consolidated Growth Rank also has a low rank of 7, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 93 of its competitors have better growth. ...read more

more
Index
Good Governace Growth Markets
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 67 67 75
Growth
7 41 35 19
Safety
Safety
55 79 49 47
Sentiment
32 83 88 26
360° View
360° View
20 93 82 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
24 23 38 13
Opinions Change
41 81 48 49
Pro Holdings
n/a 85 99 94
Market Pulse
43 92 79 15
Sentiment
32 83 88 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 67 67 75
Growth
7 41 35 19
Safety Safety
55 79 49 47
Combined
24 87 55 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
67 73 68 74
Price vs. Earnings (P/E)
57 50 61 70
Price vs. Book (P/B)
55 58 69 69
Dividend Yield
49 44 45 52
Value
63 67 67 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
10 18 20 22
Profit Growth
19 67 67 39
Capital Growth
4 31 12 66
Stock Returns
61 57 89 23
Growth
7 41 35 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
45 74 62 42
Refinancing
43 44 52 62
Liquidity
83 80 48 39
Safety Safety
55 79 49 47

Similar Stocks

Discover high‑ranked alternatives to Zydus and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.